Psimenou 2002.

Methods	Study design: active comparator, open‐label, parallel RCT Duration of study: not reported Duration of follow‐up: 12 months
Participants	Country: Greece Setting: single centre Inclusion criteria: kidney transplant recipients Number: treatment group (23); control group (20) Mean age ± SD (years): not reported Sex (M/F): not reported Exclusion criteria: not reported
Interventions	Treatment group Calcitonin (intranasal): 200 IU/d periodically for 1.5 months Treatment group Etidronate (oral) 200 mg/d for 15 days every 3 months Co‐interventions Not reported
Outcomes	BMD (lumbar spine, femoral neck, forearm) Treatment‐related hypocalcaemia Adverse events
Notes	Abstract‐only publication. Full‐text publication not identified Funding source: not reported Trial registration: not applicable as study published before end of 2005
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to permit judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unblinded study. Interventions given by different routes
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Selective reporting (reporting bias)	High risk	Patient‐centred fracture, death and graft outcomes not systematically captured or reported
Other bias	Unclear risk	Insufficient information to permit judgement